Display options
Cite
Vijayakumaran R, Tan KH, Miranda PJ, et al. Regulation of Mutant p53 Protein Expression. Front Oncol. 2015;5:284doi: 10.3389/fonc.2015.00284.
Vijayakumaran, R., Tan, K. H., Miranda, P. J., Haupt, S., & Haupt, Y. (2015). Regulation of Mutant p53 Protein Expression. Frontiers in oncology, 5284. https://doi.org/10.3389/fonc.2015.00284
Vijayakumaran, Reshma, et al. "Regulation of Mutant p53 Protein Expression." Frontiers in oncology vol. 5 (2015): 284. doi: https://doi.org/10.3389/fonc.2015.00284
Vijayakumaran R, Tan KH, Miranda PJ, Haupt S, Haupt Y. Regulation of Mutant p53 Protein Expression. Front Oncol. 2015 Dec 17;5:284. doi: 10.3389/fonc.2015.00284. eCollection 2015. PMID: 26734569; PMCID: PMC4681805.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2015 Dec 17;5:284. doi: 10.3389/fonc.2015.00284. eCollection 2015.

Regulation of Mutant p53 Protein Expression.

Frontiers in oncology

Reshma Vijayakumaran, Kah Hin Tan, Panimaya Jeffreena Miranda, Sue Haupt, Ygal Haupt

Affiliations

  1. Tumour Suppression Laboratory, Peter MacCallum Cancer Centre , Melbourne, VIC , Australia.
  2. Tumour Suppression Laboratory, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology and Department of Pathology, The University of Melbourne, Parkville, VIC, Australia; Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC, Australia.

PMID: 26734569 PMCID: PMC4681805 DOI: 10.3389/fonc.2015.00284

Abstract

For several decades, p53 has been detected in cancer biopsies by virtue of its high protein expression level which is considered indicative of mutation. Surprisingly, however, mouse genetic studies revealed that mutant p53 is inherently labile, similar to its wild type (wt) counterpart. Consistently, in response to stress conditions, both wt and mutant p53 accumulate in cells. While wt p53 returns to basal level following recovery from stress, mutant p53 remains stable. In part, this can be explained in mutant p53-expressing cells by the lack of an auto-regulatory loop with Mdm2 and other negative regulators, which are pivotal for wt p53 regulation. Further, additional protective mechanisms are acquired by mutant p53, largely mediated by the co-chaperones and their paralogs, the stress-induced heat shock proteins. Consequently, mutant p53 is accumulated in cancer cells in response to chronic stress and this accumulation is critical for its oncogenic gain of functions (GOF). Building on the extensive knowledge regarding wt p53, the regulation of mutant p53 is unraveling. In this review, we describe the current understanding on the major levels at which mutant p53 is regulated. These include the regulation of p53 protein levels by microRNA and by enzymes controlling p53 proteasomal degradation.

Keywords: Mdm2; cancer; miRNA; mutant p53; proteasomal degradation

References

  1. Oncogene. 2013 Jul 4;32(27):3286-95 - PubMed
  2. Cancer Res. 2003 Oct 15;63(20):6643-50 - PubMed
  3. Oncogene. 2013 Jun 13;32(24):2992-3000 - PubMed
  4. PLoS One. 2012;7(8):e42034 - PubMed
  5. Bioinformatics. 2011 May 15;27(10):1346-50 - PubMed
  6. Cell Death Dis. 2014 Aug 21;5:e1387 - PubMed
  7. Annu Rev Biochem. 1998;67:425-79 - PubMed
  8. EMBO J. 2002 Jul 15;21(14 ):3715-27 - PubMed
  9. Nature. 2009 Jul 23;460(7254):529-33 - PubMed
  10. Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14973-7 - PubMed
  11. Cell Cycle. 2008 Oct;7(19):3056-61 - PubMed
  12. EMBO J. 1996 Oct 1;15(19):5349-57 - PubMed
  13. EMBO J. 2011 Mar 2;30(5):846-58 - PubMed
  14. Oncogene. 2004 May 20;23 (23 ):4121-9 - PubMed
  15. J Biol Chem. 2014 Jan 3;289(1):122-32 - PubMed
  16. Proc Natl Acad Sci U S A. 2012 Sep 18;109(38):15312-7 - PubMed
  17. Cell. 2010 Feb 5;140(3):384-96 - PubMed
  18. EMBO J. 1999 Apr 1;18(7):1805-14 - PubMed
  19. Oncogene. 2014 Mar 20;33(12):1601-8 - PubMed
  20. Trends Biochem Sci. 2006 Mar;31(3):164-72 - PubMed
  21. Cell Death Dis. 2013 Oct 17;4:e867 - PubMed
  22. EMBO J. 1999 Nov 1;18(21):5943-52 - PubMed
  23. Endocr Relat Cancer. 2015 Apr;22(2):265-76 - PubMed
  24. Cold Spring Harb Perspect Biol. 2009 Dec;1(6):a000950 - PubMed
  25. EMBO J. 2009 Dec 16;28(24):3857-67 - PubMed
  26. Genes Dev. 2012 Jun 15;26(12):1268-86 - PubMed
  27. Mol Cancer. 2011 Mar 18;10:29 - PubMed
  28. Proc Natl Acad Sci U S A. 2012 Apr 3;109 (14 ):5316-21 - PubMed
  29. PLoS One. 2012;7(1):e29783 - PubMed
  30. Nature. 1997 May 15;387(6630):299-303 - PubMed
  31. Nat Struct Mol Biol. 2008 Dec;15(12 ):1334-42 - PubMed
  32. Cell Death Differ. 2011 Dec;18(12 ):1904-13 - PubMed
  33. Mol Cell Biol. 2013 Aug;33(16):3309-20 - PubMed
  34. J Mol Cell Biol. 2015 Apr;7(2):92-104 - PubMed
  35. J Hepatol. 2015 Jan;62(1):121-30 - PubMed
  36. Nat Commun. 2014 Oct 06;5:5059 - PubMed
  37. Oncogene. 2011 Apr 14;30(15):1798-811 - PubMed
  38. Nature. 1997 May 15;387(6630):296-9 - PubMed
  39. Mol Cell. 2005 May 27;18(5):601-7 - PubMed
  40. Mol Cell Biol. 1998 Mar;18(3):1517-24 - PubMed
  41. PLoS One. 2012;7(12 ):e51426 - PubMed
  42. J Mol Cell Biol. 2014 Jun;6(3):198-205 - PubMed
  43. Mol Cancer Res. 2011 May;9(5):577-88 - PubMed
  44. Curr Opin Cell Biol. 2010 Apr;22(2):124-31 - PubMed
  45. J Mol Cell Biol. 2014 Jun;6(3):192-7 - PubMed
  46. Cell Death Differ. 2012 Jun;19(6):1038-48 - PubMed
  47. Cell Rep. 2014 Aug 7;8(3):714-22 - PubMed
  48. Oncotarget. 2013 Jul;4(7):984-94 - PubMed
  49. PLoS One. 2014 Aug 12;9(8):e103497 - PubMed
  50. EMBO J. 2004 Sep 15;23(18):3689-99 - PubMed
  51. Oncogene. 2015 Feb 26;34(9):1094-104 - PubMed
  52. Cell. 2003 Mar 21;112(6):779-91 - PubMed
  53. Nucleic Acids Res. 2010 Oct;38(19):6544-54 - PubMed
  54. Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):13777-82 - PubMed
  55. Cancer Metastasis Rev. 1993 Jun;12(2):103-17 - PubMed
  56. Exp Biol Med (Maywood). 2010 Mar;235(3):278-89 - PubMed
  57. RNA. 2014 Jun;20(6):765-72 - PubMed
  58. Biochim Biophys Acta. 2014 Jan;1843(1):137-49 - PubMed
  59. Oncogene. 2008 May 29;27(24):3371-83 - PubMed
  60. Genomics. 1997 Jul 1;43(1):34-42 - PubMed
  61. Epigenetics. 2011 Sep 1;6(9):1068-77 - PubMed
  62. Mol Cell. 2006 Jul 21;23 (2):251-63 - PubMed
  63. Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8379-83 - PubMed
  64. Proc Natl Acad Sci U S A. 2005 Apr 5;102(14 ):5056-61 - PubMed
  65. Cell Death Dis. 2014 Apr 24;5:e1194 - PubMed
  66. Oncogene. 2003 Sep 4;22(38):5958-66 - PubMed
  67. Cell Death Differ. 2010 Jan;17(1):103-8 - PubMed
  68. Genes Dev. 2013 Aug 1;27(15):1718-30 - PubMed
  69. J Biol Chem. 2009 Feb 6;284(6):4031-9 - PubMed
  70. Oncogene. 1997 Sep 4;15(10 ):1179-89 - PubMed
  71. Cell Cycle. 2011 Nov 15;10(22):3938-47 - PubMed
  72. Oncogene. 2008 Jun 12;27(26):3653-61 - PubMed
  73. Autophagy. 2008 Aug;4(6):810-4 - PubMed
  74. Cell. 2009 May 15;137(4):609-22 - PubMed
  75. J Biol Chem. 2002 Aug 9;277(32):28446-58 - PubMed
  76. Nat Struct Mol Biol. 2009 Jan;16(1):23-9 - PubMed
  77. Nature. 2015 Jul 16;523(7560):352-6 - PubMed
  78. Cell Cycle. 2013 Jun 1;12 (11):1722-31 - PubMed
  79. Cell Death Dis. 2014 Dec 11;5:e1564 - PubMed
  80. Cancer Res. 2014 Jun 15;74(12 ):3218-27 - PubMed
  81. Physiol Rev. 2002 Apr;82(2):373-428 - PubMed
  82. Biomed Pharmacother. 2011 Sep;65(6):436-42 - PubMed
  83. Cell Death Dis. 2013 Apr 04;4:e574 - PubMed
  84. Genes Dev. 2009 Apr 1;23(7):862-76 - PubMed
  85. Nature. 2000 Nov 16;408(6810):307-10 - PubMed
  86. Cell. 2004 Dec 17;119(6):861-72 - PubMed
  87. J Pathol. 2006 Apr;208(5):724-32 - PubMed
  88. Oncotarget. 2014 Oct 15;5(19):9106-17 - PubMed
  89. Genes Dev. 2008 May 15;22(10 ):1337-44 - PubMed
  90. FEBS Lett. 2015 Jul 8;589(15):1958-65 - PubMed
  91. Oncogene. 2015 Apr 9;34(15):1908-18 - PubMed
  92. Mol Cell Biol. 2007 Dec;27(23 ):8284-95 - PubMed
  93. Cell. 2005 Oct 7;123(1):49-63 - PubMed
  94. Cancer Cell. 2014 Mar 17;25(3):304-17 - PubMed
  95. Cancer. 2004 Apr 15;100(8):1673-82 - PubMed
  96. Hum Mutat. 2007 Jun;28(6):622-9 - PubMed

Publication Types